Company intelligence / Profile preview
Annexin Pharmaceuticals AB
Stockholm, Swedenannexinpharma.com ↗
- Ownership
- Private
- Employees
- ~4
- Development stage
- Other
01
Overview
Annexin Pharmaceuticals has completed a Phase 2a study for their drug candidate ANXV in Retinal Vein Occlusion (RVO). Topline results showed a favorable safety profile with 12 out of 14 patients improving or having stable disease with no or a single anti-VEGF treatment over a 4-month follow-up period.
- Therapeutic areas
- OphthalmologyOncologyCardiovascular
- Modalities
- Recombinant proteinProtein drug conjugate
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Annexin Pharmaceuticals AB.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Annexin Pharmaceuticals AB.